Refine by
International Symposium On Medicinal Articles & Analysis: Older
54 news found
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. The stock is trading at $2.0050, up $0.8750, gaining +77.0925% on volume of over 8o ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important treatment option ...
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
ByArdigen
Ocean Biomedical’s innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. Ocean Biomedical’s initial core portfolios in oncology, fibrosis, and infectious diseases – all based on new target discoveries enabling first-in-class drug and vaccine ...
PharmAI attends the XXVll EFMC International Symposium on Medicinal Chemistry held in Nice, France from September 4-8 2022. ...
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A study, which demonstrate that the Cellworks Biosimulation Platform and SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) for non-small cell lung cancer (NSCLC) patients and can provide ...
BOSTON – July 26, 2022 – Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development ...
ByElucid
Arterius are pleased to welcome Prof. Patrick Serruys and Dr. Yoshi Onuma to our clinical advisory board. Prof. Serruys (Imperial College, London) will become chair of the clinical advisory board, also now featuring Dr. Onuma (Cardialysis, Netherlands) and Dr. Rasha Al-Lamee (Imperial College, London). Prof. Patrick W. Serruys is is a professor of Interventional Cardiology at the ...
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Aleksandra Rizo, M.D., Ph.D., will join the company as President and Head of ...
ByBayer AG
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB). Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...
ATsens developed the first wearable long-term continuous ECG monitor in Korea. Honorary professor Lee Man-Yeong was appointed as CMO and head of the data center for medical advice and data center establishment. He’s a professor of Circulatory Internal Medicine and an authority in the field of arrhythmia, who continued research and treatment of arrhythmia during his tenure. Participate ...
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm ...
Diffusion Pharmaceuticals Inc.(NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced a significant expansion of its Scientific Advisory Board (SAB) to include five prominent radiation and medical oncologists to help guide ...
ByCervoMed
The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating hospitals in Germany to begin to negotiate payment for Revita from statutory health insurers LEXINGTON, MA., February 8, 2022 – Fractyl Health, an organ-editing metabolic therapeutics company ...
Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery ...
Dr. Edsel Abud has joined Stem Pharm’s talented team of Advisors. While attending University of California Irvine for his MD and PhD as part of the NIH's Medical Scientist Training Program (MSTP), Dr. Abud notably developed one of the first methods to generate human microglia from stem cells, showing their functional genomics and how they play a role in health and disease. Dr. Abud was also ...
Elizabeth Tarka, M.D. appointed Chief Medical Officer A. Brian Davis named Chief Financial Officer XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief Financial Officer. These experienced pharmaceutical ...
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to ...
ByAlkermes